Summary
Background To investigate the impact of goggles on their health and clinical practice during management of patients with COVID-19.
Methods 231 nurse practitioners were enrolled who worked in isolation region in designated hospitals to admit patients with COVID-19 in China. Demographic data, goggle-associated symptoms and underlying reasons, incidence of medical errors or exposures, the effects of fog in goggles on practice were all collected. Data were stratified and analyzed by age or working experience. Risk factors of goggle-associated medical errors were analyzed by multivariable logistical regression analysis.
Findings Goggle-associated symptoms and foggy goggles widely presented in nurses. The most common symptoms were headache, skin pressure injury and dizziness. Headache, vomit and nausea were significantly fewer reported in nurses with longer working experience while rash occurred higher in this group. The underlying reasons included tightness of goggles, unsuitable design and uncomfortable materials. The working status of nurses with more working experience was less impacted by goggles. 11.3% nurses occurred medical exposures in clinical practice while 19.5% nurses made medical errors on patients. The risk factors for medical errors were time interval before adapting to goggle-associated discomforts, adjusting goggles and headache.
Interpretation Goggle-associated symptoms and fog can highly impact the working status and contribute to medical errors during management of COVID-19. Increased the experience with working in PPE through adequate training and psychological education may benefit for relieving some symptoms and improving working status. Improvement of goggle design during productive process was strongly suggested to reduce incidence of discomforts and medical errors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is supported by fund of General Hospital of Western Theater Command (No. 2019ZT10)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email address: He Xiao-huan, 6184342{at}qq.com; Feng Yan-ru, 254966486{at}qq.com; Li Gao-ming, gaomlitmmu{at}outlook.com; Pang Xiao-jiao, 112934949{at}qq.com; Chen Ting, 13391326{at}qq.com; Zhou Ya-li, 16014523{at}qq.com; Zhang Hao, 470955474{at}qq.com; Lang Jing, 378474892{at}qq.com; Li Li-min, 58201164{at}qq.com; Feng Li, 409443408{at}qq.com; He Xin, 331326018{at}qq.com; Zheng Wei, zhengweipaper{at}sina.com; Miao Hong-ming, hongmingmiao{at}sina.com; Wang Yong-hua, 694935018{at}qq.com; Kang Xia, kxpaper{at}sina.com;
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.